Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics director Stephanie Okey exercised stock options and sold shares in a pre-planned transaction. On March 10, 2026, she exercised options to acquire 15,167 shares of common stock at an exercise price of $33.63 per share.
On the same date, she sold 15,167 common shares in open-market transactions at a sale price of $70.00 per share pursuant to a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, she holds 8,000 shares of PTC Therapeutics common stock directly.
Matthew Klein reported proposed and recent sales of Common Stock. The filing lists a proposed sale of 2,662 shares on 03/11/2026 tied to restricted stock vesting. The filing also records multiple sales in the prior three months, including 8,089 shares on 12/30/2025 and 7,371 shares on 02/18/2026, with dollar amounts shown for each trade.
Form 144 filing reports proposed and recent sales of common stock. The notice lists 15,167 shares of Common Stock associated with Fidelity Brokerage Services LLC with an entry dated 03/10/2026. The filing also records that Stephanie Okey sold 6,333 shares on 03/05/2026 for $401,385.54.
PTC Therapeutics, Inc. director Stephanie Okey sold 6,333 shares of common stock in an open-market transaction on March 5, 2026 at $63.38 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After this transaction, she directly holds 8,000 PTC Therapeutics shares.
PTC Therapeutics executive Lee Scott Golden reported an open-market stock sale. On March 5, 2026, the company’s EVP & Chief Medical Officer sold 10,000 shares of PTC Therapeutics common stock at a price of $63.38 per share.
The sale was executed under a written Rule 10b5-1 trading plan that Golden adopted on December 4, 2025. After this transaction, Golden directly owns 79,944 shares of PTC Therapeutics common stock.
PTC THERAPEUTICS, INC. executive Neil Gregory Almstead, the Chief Technical Operations Officer, reported an indirect open-market sale of common stock by his spouse. On March 5, 2026, his spouse sold 3,989 shares of common stock at $63.38 per share in a sale classified as an open-market or private transaction.
This transaction was carried out under a written Rule 10b5-1 trading plan adopted by Almstead on November 26, 2025. Following the sale, his spouse held 2,737 shares of common stock indirectly, while Almstead held an additional 112,140 shares of common stock directly.
Fidelity Brokerage Services LLC filed a Form 144 proposing the sale of Common shares of PTCT. The notice lists restricted stock vesting events on 06/18/2024 (1,334 shares), 02/18/2025 (1,333 shares), 02/19/2025 (1,333 shares) and 01/03/2026 (2,333 shares). The filing identifies the sales agent and class of securities.
PTCT holders sold common stock in multiple transactions disclosed on Form 144. The excerpt lists sale lots by Neil G. Almstead and Zheng Y. Almstead between 01/06/2026 and 02/18/2026, including examples of 1,279 shares for $98,415.98 and 3,056 shares for $211,953.77.
The entries show routine dispositions tied to restricted stock vesting and ESPP purchases in prior years; amounts and prices are itemized per sale date.
Lee S. Golden reported sales of common stock under Rule 144. The filing shows sales of 1,340 shares on 01/06/2026 for $103,109.78, 642 shares on 01/07/2026 for $49,744.60, 866 shares on 01/08/2026 for $66,204.92, and 2,484 shares on 02/18/2026 for $172,281.80.
The filing also lists multiple prior restricted stock vesting entries issued by the company on various dates, including vesting quantities such as 1,287 on 01/09/2023 and 1,885 on 01/05/2024, shown as background to the sold securities.
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported open-market sales of a total of 3,019 shares of common stock on February 19, 2026. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024, occurred at weighted-average prices of $68.54 and $69.82 per share, based on multiple trades within disclosed price ranges from $67.99 to $70.18. Following these sales, Boulding directly held 105,212 shares of PTC Therapeutics common stock.